Evaluation of anti-liver cancer activity and anticancer mechanism of one novel small molecule compound (THY-10A62) targeting FAK pathway.

ABSTRACT:

Introduction

Focal adhesion kinase (FAK) is a promising therapeutic target, and its aberrant overexpression has been implicated in the growth and metastasis of multiple cancers, including hepatocellular carcinoma (HCC). This study preliminarily evaluated the antitumor activity and mechanisms of THY-10A62, a novel FAK inhibitor, in vivo.

Methods

The maximum tolerated dose (MTD) and median lethal dose (LD₅₀) of THY-10A62 were determined in ICR mice using dose-escalation survival and tolerability assessments. Antitumor efficacy was tested in an HCC-LM3 cell line-derived xenograft (CDX) model and in patient-derived xenograft (PDX) models of liver cancer. FAK pathway modulation was examined using a protein phosphorylation chip coupled with network pharmacology a

SUBMITTER: Huang W 

PROVIDER: S-EPMC12433887 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature